Laura Pazzagli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Pazzagli has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn E. Cesta
Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
8 shared publications - Björn Pasternak
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
4 shared publications - Marie Linder
Department of Medicine Solna Centre for Pharmacoepidemiology, Karolinska Institutet Stockholm Sweden
4 shared publications - Christos Karampelias
Institute of Diabetes and Regeneration Research, Helmholtz Munich, Neuherberg, Germany
3 shared publications - Ingvild Odsbu
Department of Chronic Diseases Norwegian Institute of Public Health Oslo Norway
3 shared publications - Olov Andersson
Uppsala University 1 Department of Medical Cell Biology BMC, Husargatan 3, 75123 Uppsala
3 shared publications
Latest Publications
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , 1232-1243
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
There are concerns about a possible link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION). To examine whether use of GLP-1RAs increases risk for AION, which predominantly comprises NAION. Nationwide, register-based, cohort study. Sweden, 2013 to 2024. Initiators of GLP-1RAs compared with initiators of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Anterior ischemic optic neuropathy in the national patient register. Adjusted risk differences (RDs) and risk ratios (RRs) were estimated using propensity score weighting. Median follow-up was 1.6 years (IQR, 0.7 to 3.1 years) for GLP-1RA users and 1.5 years (IQR, 0.7 to 2.9 years) for SGLT-2 inhibitor users. Sixty-two of 107 518 GLP-1RA users and 64 of 185 898 SGLT-2 inhibitor users experienced AION. Risks were 0.04% versus 0.02% (RD, 0.02% [95% CI, 0.00% to 0.03%]; RR, 1.93 [CI, 1.00 to 3.73]) at 1 year and 0.12% versus 0.07% (RD, 0.05% [CI, 0.00% to 0.10%]; RR, 1.69 [CI, 0.95 to 3.01]) at 5 years. The differences were substantially attenuated in analyses restricted to patients receiving metformin at baseline (1 year: RD, 0.01% [CI, -0.01% to 0.02%]; RR, 1.40 [CI, 0.64 to 3.05]; 3 years: RD, 0.01% [CI, -0.02% to 0.04%]; RR, 1.24 [CI, 0.68 to 2.26]; 5 years: RD, 0.02% [CI, -0.04% to 0.08%]; RR, 1.23 [CI, 0.65 to 2.33]). Few outcome events, unmeasured confounding, and limited generalizability to GLP-1RA users without diabetes. The relative risk for AION was higher with GLP-1RA use compared with SGLT-2 inhibitor use in type 2 diabetes. However, absolute risks were small, and the RDs were substantially reduced in analyses restricted to patients receiving metformin to better account for confounding by diabetes severity, suggesting observed increases in risk may reflect residual confounding. Karolinska Institutet, Swedish Society of Medicine, Swedish Research Council, and Region Stockholm.
- 1 September 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (9) , 1232-1243
Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy
There are concerns about a possible link between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION). To examine whether use of GLP-1RAs increases risk for AION, which predominantly comprises NAION. Nationwide, register-based, cohort study. Sweden, 2013 to 2024. Initiators of GLP-1RAs compared with initiators of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Anterior ischemic optic neuropathy in the national patient register. Adjusted risk differences (RDs) and risk ratios (RRs) were estimated using propensity score weighting. Median follow-up was 1.6 years (IQR, 0.7 to 3.1 years) for GLP-1RA users and 1.5 years (IQR, 0.7 to 2.9 years) for SGLT-2 inhibitor users. Sixty-two of 107 518 GLP-1RA users and 64 of 185 898 SGLT-2 inhibitor users experienced AION. Risks were 0.04% versus 0.02% (RD, 0.02% [95% CI, 0.00% to 0.03%]; RR, 1.93 [CI, 1.00 to 3.73]) at 1 year and 0.12% versus 0.07% (RD, 0.05% [CI, 0.00% to 0.10%]; RR, 1.69 [CI, 0.95 to 3.01]) at 5 years. The differences were substantially attenuated in analyses restricted to patients receiving metformin at baseline (1 year: RD, 0.01% [CI, -0.01% to 0.02%]; RR, 1.40 [CI, 0.64 to 3.05]; 3 years: RD, 0.01% [CI, -0.02% to 0.04%]; RR, 1.24 [CI, 0.68 to 2.26]; 5 years: RD, 0.02% [CI, -0.04% to 0.08%]; RR, 1.23 [CI, 0.65 to 2.33]). Few outcome events, unmeasured confounding, and limited generalizability to GLP-1RA users without diabetes. The relative risk for AION was higher with GLP-1RA use compared with SGLT-2 inhibitor use in type 2 diabetes. However, absolute risks were small, and the RDs were substantially reduced in analyses restricted to patients receiving metformin to better account for confounding by diabetes severity, suggesting observed increases in risk may reflect residual confounding. Karolinska Institutet, Swedish Society of Medicine, Swedish Research Council, and Region Stockholm.
- Open Access
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in a National Population of Patients With Type 1 Diabetes
Background: GLP-1 receptor agonists and SGLT2 inhibitors improve cardiometabolic risk factors in type 1 diabetes, but lack approval for this condition, partly due to concerns regarding safety. We assessed the use of these drugs in a national population of individuals with type 1 diabetes. Methods: We conducted an open cohort study in Sweden including all patients aged ≥18 years with type 1 diabetes (2007-2024). We calculated yearly prevalence of GLP-1 receptor agonist and SGLT2 inhibitor use based on prescription fills. We used logistic regression to identify patient characteristics associated with use of each drug. Further, we assessed the proportion of patients who had elevated HbA1c or obesity, without receiving any of the drugs. We assessed the incidence of ketoacidosis among new SGLT2 inhibitor users. Findings: In total, 72698 patients were included. In 2024, median (IQR) age was 48 (33, 63) years and 44·2% were women. Use of both drug classes increased during the study period and reached 5·5% in 2024 for GLP-1 receptor agonist and 0·9% for SGLT2 inhibitors (peak in 2022: 1·1%). For both drug classes, use was associated with older age, obesity, poor glucose control, chronic kidney disease and cardiovascular comorbidities, although SGLT2 inhibitors showed stronger associations with the latter two. In 2024, 24.5% of the patients had an HbA1c of ≥64 mmol/mol and 16.8% had obesity and were not treated with either drug class. Among 1,291 first-time SGLT2 inhibitor users, the on-treatment incidence rate of diabetic ketoacidosis was 24·9 (95% CI 18.4-31.5) events per 1000 person-years. Interpretation: In a national population of patients type 1 diabetes, use of GLP-1 receptor agonists and SGLT2 inhibitors has increased but remains low at 5.5% for GLP-1 receptor agonists and 0.9% for SGLT2 inhibitors in 2024. Potential may remain for improving cardiometabolic risk factors among type 1 diabetes patients using ancillary treatment with SGLT2 inhibitors and GLP-1 receptor agonists, but strategies for safe use need to be developed, especially with respect to the diabetic ketoacidosis risk associated with SGLT2 inhibitors.
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUse of GLP-1 Receptor Agonists and SGLT2 Inhibitors in a National Population of Patients With Type 1 Diabetes
Background: GLP-1 receptor agonists and SGLT2 inhibitors improve cardiometabolic risk factors in type 1 diabetes, but lack approval for this condition, partly due to concerns regarding safety. We assessed the use of these drugs in a national population of individuals with type 1 diabetes. Methods: We conducted an open cohort study in Sweden including all patients aged ≥18 years with type 1 diabetes (2007-2024). We calculated yearly prevalence of GLP-1 receptor agonist and SGLT2 inhibitor use based on prescription fills. We used logistic regression to identify patient characteristics associated with use of each drug. Further, we assessed the proportion of patients who had elevated HbA1c or obesity, without receiving any of the drugs. We assessed the incidence of ketoacidosis among new SGLT2 inhibitor users. Findings: In total, 72698 patients were included. In 2024, median (IQR) age was 48 (33, 63) years and 44·2% were women. Use of both drug classes increased during the study period and reached 5·5% in 2024 for GLP-1 receptor agonist and 0·9% for SGLT2 inhibitors (peak in 2022: 1·1%). For both drug classes, use was associated with older age, obesity, poor glucose control, chronic kidney disease and cardiovascular comorbidities, although SGLT2 inhibitors showed stronger associations with the latter two. In 2024, 24.5% of the patients had an HbA1c of ≥64 mmol/mol and 16.8% had obesity and were not treated with either drug class. Among 1,291 first-time SGLT2 inhibitor users, the on-treatment incidence rate of diabetic ketoacidosis was 24·9 (95% CI 18.4-31.5) events per 1000 person-years. Interpretation: In a national population of patients type 1 diabetes, use of GLP-1 receptor agonists and SGLT2 inhibitors has increased but remains low at 5.5% for GLP-1 receptor agonists and 0.9% for SGLT2 inhibitors in 2024. Potential may remain for improving cardiometabolic risk factors among type 1 diabetes patients using ancillary treatment with SGLT2 inhibitors and GLP-1 receptor agonists, but strategies for safe use need to be developed, especially with respect to the diabetic ketoacidosis risk associated with SGLT2 inhibitors.
- Open Access
- 8 January 2026
- Published by BMJ in BMJ Connections Mental Health
- Vol. 1 (1) , e000026
Prevalence and characteristics of women with bipolar disorder discontinuing lithium treatment in pregnancy: a Swedish cohort study leveraging prescription free-text information
Objectives: Lithium is a first-line treatment option for preventing relapse in bipolar disorder but may be discontinued periconceptionally due to safety concerns. We aimed to examine the prevalence of lithium discontinuation among pregnant women with bipolar disorder in Sweden, using a novel method to identify daily dose, and to describe the characteristics of the discontinuers and continuers. Design: Cohort study. Setting: Swedish population-based registers (2006–2019). Participants: Women with bipolar disorder and an ongoing lithium treatment episode 6 months prior to pregnancy were identified. Natural language processing (NLP) of the prescription free-text information was used to define the daily dose, and to construct treatment episodes. Interventions: Not applicable. Main outcome measures: Lithium discontinuation was defined as the end of a continuous treatment episode between 6 months before the start of pregnancy and delivery. The performance of the NLP method was compared with manual review of the prescription texts. The characteristics of the discontinuers and the continuers were described, including psychiatric comorbidities and other medications used. Findings: In 662 pregnancies, 438 women (70%) discontinued lithium treatment, the majority in prepregnancy or first trimester. The NLP method showed high internal validity compared with manual review of prescription texts; however, the estimated date of discontinuation could not be validated against measures of actual drug use. Discontinuers, compared with continuers, had a higher prevalence of comorbid substance use disorder (7.8% vs 2.7%), personality disorder (11.4% vs 6.0%) and attention-deficit/hyperactivity disorder (13.5% vs 7.6%). After discontinuation, there was no increased use of other mood stabilisers, and 46% had a new dispensation of lithium within 6–12 months. Conclusions: The majority of lithium-treated women with bipolar disorder discontinued treatment around the start of pregnancy; however, lithium discontinuation is also common outside pregnancy, and the reason for discontinuation in our cohort remains unknown. Discontinuers had a higher rate of psychiatric comorbidity, and switches to other mood stabilising treatments did not appear to be common. Given that both the peripartum period and withdrawal of mood stabilising treatment may contribute to increased risk of relapse, the consequences of lithium discontinuation for maternal psychiatric health should be studied further.
- 8 January 2026
- Published by BMJ in BMJ Connections Mental Health
- Vol. 1 (1) , e000026
Open AccessPrevalence and characteristics of women with bipolar disorder discontinuing lithium treatment in pregnancy: a Swedish cohort study leveraging prescription free-text information
Objectives: Lithium is a first-line treatment option for preventing relapse in bipolar disorder but may be discontinued periconceptionally due to safety concerns. We aimed to examine the prevalence of lithium discontinuation among pregnant women with bipolar disorder in Sweden, using a novel method to identify daily dose, and to describe the characteristics of the discontinuers and continuers. Design: Cohort study. Setting: Swedish population-based registers (2006–2019). Participants: Women with bipolar disorder and an ongoing lithium treatment episode 6 months prior to pregnancy were identified. Natural language processing (NLP) of the prescription free-text information was used to define the daily dose, and to construct treatment episodes. Interventions: Not applicable. Main outcome measures: Lithium discontinuation was defined as the end of a continuous treatment episode between 6 months before the start of pregnancy and delivery. The performance of the NLP method was compared with manual review of the prescription texts. The characteristics of the discontinuers and the continuers were described, including psychiatric comorbidities and other medications used. Findings: In 662 pregnancies, 438 women (70%) discontinued lithium treatment, the majority in prepregnancy or first trimester. The NLP method showed high internal validity compared with manual review of prescription texts; however, the estimated date of discontinuation could not be validated against measures of actual drug use. Discontinuers, compared with continuers, had a higher prevalence of comorbid substance use disorder (7.8% vs 2.7%), personality disorder (11.4% vs 6.0%) and attention-deficit/hyperactivity disorder (13.5% vs 7.6%). After discontinuation, there was no increased use of other mood stabilisers, and 46% had a new dispensation of lithium within 6–12 months. Conclusions: The majority of lithium-treated women with bipolar disorder discontinued treatment around the start of pregnancy; however, lithium discontinuation is also common outside pregnancy, and the reason for discontinuation in our cohort remains unknown. Discontinuers had a higher rate of psychiatric comorbidity, and switches to other mood stabilising treatments did not appear to be common. Given that both the peripartum period and withdrawal of mood stabilising treatment may contribute to increased risk of relapse, the consequences of lithium discontinuation for maternal psychiatric health should be studied further.
- Open Access
- 23 September 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in type 2 diabetes: a nationwide comparative effectiveness study
Background: Combination therapy is gaining attention in type 2 diabetes management due to its potential to reach glycaemic goals within a shorter period. However, the long-term comparative cardiorenal effectiveness of fixed- versus loose-dose combinations remains unclear. This study aimed to assess whether oral antidiabetic fixed-dose combination (FDC) therapy is associated with improved cardiorenal outcomes in adults with type 2 diabetes compared with loose-dose combination (LDC) therapy. A secondary objective was to evaluate the mediating role of medication adherence in these associations. Methods: This population-based, new-user, active-comparator cohort study used Swedish national registers. Propensity score matching without replacement was applied. Study outcomes included acute myocardial infarction, atrial fibrillation, unstable angina, heart failure, ischaemic stroke, and eGFR < 30 ml/min/1.73m2. Associations with cardiorenal outcomes were assessed using Cox regression. Adherence was defined as the proportion of days covered > 80% during the first year. Results: The median follow-up time was 4.0 years for cardiovascular outcomes and 3.8 years for kidney outcomes. In the matched cohort (mean age 62 years; 67% male), FDC users had higher treatment adherence (68.6 vs. 46.5%). FDC was associated with a lower rate of heart failure (HR = 0.88; 95% CI 0.79, 0.99), with adherence mediating 47% of this association. In people aged ≥ 65 years, FDC was associated with a lower rate of heart failure (HR = 0.79; 95% CI 0.69, 0.91). The observed association was attenuated with further matching for diabetes duration or when drugs were matched at the ATC code level. No associations between FDC use and other outcomes were identified. Conclusions: FDC therapy in people with type 2 diabetes was associated with a lower rate of heart failure, particularly in older adults. Higher medication adherence appeared to mediate nearly half of this association.
- 23 September 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-12
Open AccessFixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal outcomes in type 2 diabetes: a nationwide comparative effectiveness study
Background: Combination therapy is gaining attention in type 2 diabetes management due to its potential to reach glycaemic goals within a shorter period. However, the long-term comparative cardiorenal effectiveness of fixed- versus loose-dose combinations remains unclear. This study aimed to assess whether oral antidiabetic fixed-dose combination (FDC) therapy is associated with improved cardiorenal outcomes in adults with type 2 diabetes compared with loose-dose combination (LDC) therapy. A secondary objective was to evaluate the mediating role of medication adherence in these associations. Methods: This population-based, new-user, active-comparator cohort study used Swedish national registers. Propensity score matching without replacement was applied. Study outcomes included acute myocardial infarction, atrial fibrillation, unstable angina, heart failure, ischaemic stroke, and eGFR < 30 ml/min/1.73m2. Associations with cardiorenal outcomes were assessed using Cox regression. Adherence was defined as the proportion of days covered > 80% during the first year. Results: The median follow-up time was 4.0 years for cardiovascular outcomes and 3.8 years for kidney outcomes. In the matched cohort (mean age 62 years; 67% male), FDC users had higher treatment adherence (68.6 vs. 46.5%). FDC was associated with a lower rate of heart failure (HR = 0.88; 95% CI 0.79, 0.99), with adherence mediating 47% of this association. In people aged ≥ 65 years, FDC was associated with a lower rate of heart failure (HR = 0.79; 95% CI 0.69, 0.91). The observed association was attenuated with further matching for diabetes duration or when drugs were matched at the ATC code level. No associations between FDC use and other outcomes were identified. Conclusions: FDC therapy in people with type 2 diabetes was associated with a lower rate of heart failure, particularly in older adults. Higher medication adherence appeared to mediate nearly half of this association.
- Open Access
- 28 February 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70174
Longitudinal Trajectories of Antidiabetic Medication Adherence Over 5 Years From Treatment Initiation—A Swedish Nationwide Cohort Study
Patients' longitudinal adherence to antidiabetic medication in routine clinical care remains unexplored. This study aimed to identify adherence groups among individuals with type 2 diabetes with up to 1 and 5 years of follow‐up. This was a register‐based cohort study using data from Swedish national health and population registers and the National Diabetes Register (2006–2022). New users of blood glucose–lowering drugs (other than insulin) were identified. Trajectories of the proportion of days covered (PDC) by any antidiabetic medication, including insulin, over 1‐ and 5‐year periods were clustered using k‐means for longitudinal data. Analyses up to 1‐ and 5‐year follow‐up periods included 75,421 individuals with an overall mean PDC of 0.7 and 283,795 individuals with an overall mean PDC of 0.3, respectively. K‐means clustering identified two main adherence groups. For the 1‐year follow‐up, 70.6% of individuals were in the cluster with a higher mean PDC (0.9) and 29.4% in the cluster with a lower mean PDC (0.4). The corresponding figures for the 5‐year follow‐up were 36.9% (higher mean PDC [0.9]) and 63.1% (lower mean PDC [0.3]). Clusters with higher mean trajectories of PDC included more men, older individuals, patients using drugs from only one antidiabetic medication class, and noninsulin users during follow‐up. Mean trajectories of adherence decreased mainly during the first year. This study identified a substantial problem with longitudinal adherence to any antidiabetic medication, with a low proportion of individuals clustered as having higher adherence during the 5‐year follow‐up. Results suggest the need for interventions via follow‐up strategies aiming at monitoring and improving continuous treatment management while considering tailored treatment strategies.
- 28 February 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70174
Open AccessLongitudinal Trajectories of Antidiabetic Medication Adherence Over 5 Years From Treatment Initiation—A Swedish Nationwide Cohort Study
Patients' longitudinal adherence to antidiabetic medication in routine clinical care remains unexplored. This study aimed to identify adherence groups among individuals with type 2 diabetes with up to 1 and 5 years of follow‐up. This was a register‐based cohort study using data from Swedish national health and population registers and the National Diabetes Register (2006–2022). New users of blood glucose–lowering drugs (other than insulin) were identified. Trajectories of the proportion of days covered (PDC) by any antidiabetic medication, including insulin, over 1‐ and 5‐year periods were clustered using k‐means for longitudinal data. Analyses up to 1‐ and 5‐year follow‐up periods included 75,421 individuals with an overall mean PDC of 0.7 and 283,795 individuals with an overall mean PDC of 0.3, respectively. K‐means clustering identified two main adherence groups. For the 1‐year follow‐up, 70.6% of individuals were in the cluster with a higher mean PDC (0.9) and 29.4% in the cluster with a lower mean PDC (0.4). The corresponding figures for the 5‐year follow‐up were 36.9% (higher mean PDC [0.9]) and 63.1% (lower mean PDC [0.3]). Clusters with higher mean trajectories of PDC included more men, older individuals, patients using drugs from only one antidiabetic medication class, and noninsulin users during follow‐up. Mean trajectories of adherence decreased mainly during the first year. This study identified a substantial problem with longitudinal adherence to any antidiabetic medication, with a low proportion of individuals clustered as having higher adherence during the 5‐year follow‐up. Results suggest the need for interventions via follow‐up strategies aiming at monitoring and improving continuous treatment management while considering tailored treatment strategies.
- Open Access
- 26 February 2025
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 79 (8) , 571-579
Differential use of antidiabetic medication related to income, cohabitation and area of residence: a Swedish nationwide cohort study
Background Poor adherence to antidiabetic medication in individuals with type 2 diabetes (T2D) may lead to increased risk of morbidity and mortality. Socioeconomic and demographic factors associated with non-adherence have been mainly identified via cross-sectional studies. To investigate the association between antidiabetic medication adherence and income, cohabitation and area of residence. Methods Register-based cohort study of individuals with T2D living in Sweden and initiating antidiabetic treatment between 2006 and 2022. Confounding adjustment and competing events were accounted for via inverse probability of treatment and censoring weighting. Exposures were disposable income, social income support, cohabitation status and area of residence. Outcomes were antidiabetic medication adherence during the first year from treatment initiation and treatment interruption at 12 and 60 months. Results This study included 594 918 individuals with T2D. Low disposable income (adjusted OR: 1.18, 95% CI: (1.14 to 1.21)), social income support (1.09, (1.05 to 1.14)), living in large cities (1.28, (1.24 to 1.31)) and cohabitation (1.09, (1.06 to 1.11)) were associated with non-adherence (proportion of days covered ≤0.2), as compared with high adherence (proportion of days covered >0.8). Consistently, treatment interruption was associated with social income support (relative risk ratio at 12 months: 1.10, (1.06 to 1.14) and at 60 months 1.02 (1.00 to 1.05)), living in large cities (1.13, (1.12 to 1.14); 1.08, (1.07 to 1.08)) and low income (1.05, (1.03 to 1.07); 1.01, (1.00 to 1.02)). Conclusions Low income levels, cohabitation and living in large cities were associated with non-adherence to antidiabetic medication and risk of treatment interruption. The results highlight the need for targeted interventions aiming at improving adherence to treatments both at patient and healthcare system levels.
- 26 February 2025
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 79 (8) , 571-579
Open AccessDifferential use of antidiabetic medication related to income, cohabitation and area of residence: a Swedish nationwide cohort study
Background Poor adherence to antidiabetic medication in individuals with type 2 diabetes (T2D) may lead to increased risk of morbidity and mortality. Socioeconomic and demographic factors associated with non-adherence have been mainly identified via cross-sectional studies. To investigate the association between antidiabetic medication adherence and income, cohabitation and area of residence. Methods Register-based cohort study of individuals with T2D living in Sweden and initiating antidiabetic treatment between 2006 and 2022. Confounding adjustment and competing events were accounted for via inverse probability of treatment and censoring weighting. Exposures were disposable income, social income support, cohabitation status and area of residence. Outcomes were antidiabetic medication adherence during the first year from treatment initiation and treatment interruption at 12 and 60 months. Results This study included 594 918 individuals with T2D. Low disposable income (adjusted OR: 1.18, 95% CI: (1.14 to 1.21)), social income support (1.09, (1.05 to 1.14)), living in large cities (1.28, (1.24 to 1.31)) and cohabitation (1.09, (1.06 to 1.11)) were associated with non-adherence (proportion of days covered ≤0.2), as compared with high adherence (proportion of days covered >0.8). Consistently, treatment interruption was associated with social income support (relative risk ratio at 12 months: 1.10, (1.06 to 1.14) and at 60 months 1.02 (1.00 to 1.05)), living in large cities (1.13, (1.12 to 1.14); 1.08, (1.07 to 1.08)) and low income (1.05, (1.03 to 1.07); 1.01, (1.00 to 1.02)). Conclusions Low income levels, cohabitation and living in large cities were associated with non-adherence to antidiabetic medication and risk of treatment interruption. The results highlight the need for targeted interventions aiming at improving adherence to treatments both at patient and healthcare system levels.
- Open Access
- 26 November 2024
- Published by S. Karger AG in Obesity Facts
- Vol. 18 (2) , 130-138
Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about potential inequalities for both patient groups. This study aimed to describe socioeconomic and demographic characteristics of on- and off-label users of GLP-1 receptor agonists in persons without a diagnosis of diabetes. Methods: This is a Swedish descriptive register-based cohort study of persons who filled a prescription of a GLP-1 receptor agonist at least once during 2018–2022. Individuals were excluded from the study population if they had a diagnosis of diabetes or previous prescription fills of insulin/analogs at any time prior to the first filled prescription of a GLP-1 receptor agonist. Socioeconomic and demographic characteristics were described overall and stratified by sex and prior use of anti-obesity medications. Off-label use was defined by filled prescriptions of GLP-1 receptor agonists which are indicated for diabetes treatment. Results: The study population included 16,436 individuals, of which 70.1% were women, 30.7% had previously filled a prescription of anti-obesity medications, and 65.3% had Sweden as country of origin and 17.2% an Asian country. In the analyses stratified by sex, women were more likely to have an education longer than 9 years (84.8% vs. 78.3% in men). Nonetheless, women had lower annual individual (2,891.3 vs. 4,004.9 in men) and family disposable income (5,645.5 vs. 6,092.5 in men). Overall, on-label prescription was higher in women (49.2% vs. 30.9% in men), while off-label was more common among men (69% vs. 51% in women). Trends of GLP-1 users per 1,000 inhabitants showed four-fold variation between counties. Conclusion: High family disposable income and male sex are common among off-label GLP-1 receptor agonist users compared to users of the only on-label GLP-1 receptor agonist available in Sweden during the study period. Large variation between counties indicates different clinical practices and guideline interpretations.
- 26 November 2024
- Published by S. Karger AG in Obesity Facts
- Vol. 18 (2) , 130-138
Open AccessSocioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about potential inequalities for both patient groups. This study aimed to describe socioeconomic and demographic characteristics of on- and off-label users of GLP-1 receptor agonists in persons without a diagnosis of diabetes. Methods: This is a Swedish descriptive register-based cohort study of persons who filled a prescription of a GLP-1 receptor agonist at least once during 2018–2022. Individuals were excluded from the study population if they had a diagnosis of diabetes or previous prescription fills of insulin/analogs at any time prior to the first filled prescription of a GLP-1 receptor agonist. Socioeconomic and demographic characteristics were described overall and stratified by sex and prior use of anti-obesity medications. Off-label use was defined by filled prescriptions of GLP-1 receptor agonists which are indicated for diabetes treatment. Results: The study population included 16,436 individuals, of which 70.1% were women, 30.7% had previously filled a prescription of anti-obesity medications, and 65.3% had Sweden as country of origin and 17.2% an Asian country. In the analyses stratified by sex, women were more likely to have an education longer than 9 years (84.8% vs. 78.3% in men). Nonetheless, women had lower annual individual (2,891.3 vs. 4,004.9 in men) and family disposable income (5,645.5 vs. 6,092.5 in men). Overall, on-label prescription was higher in women (49.2% vs. 30.9% in men), while off-label was more common among men (69% vs. 51% in women). Trends of GLP-1 users per 1,000 inhabitants showed four-fold variation between counties. Conclusion: High family disposable income and male sex are common among off-label GLP-1 receptor agonist users compared to users of the only on-label GLP-1 receptor agonist available in Sweden during the study period. Large variation between counties indicates different clinical practices and guideline interpretations.
- Open Access
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2438269
Postpartum Psychiatric Outcomes and Sick Leave After Discontinuing SSRI or SNRI in Pregnancy
Antidepressant use in reproductive-aged women has increased over the last decades,1 but there is little guidance on the management of treatment for women who become pregnant.2 Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the most commonly used classes of antidepressants in pregnant women,3 and it is consistently reported that approximately half of women discontinue use before or during pregnancy.4,5 While most pregnant women use SSRIs or SNRIs for depression or anxiety, such medications are also used in women being treated for other psychiatric conditions (eg, insomnia, obsessive-compulsive disorder, eating disorders, and bipolar or psychotic disorders),3 which are known to carry a higher risk for adverse postpartum psychiatric outcomes.6
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2438269
Open AccessPostpartum Psychiatric Outcomes and Sick Leave After Discontinuing SSRI or SNRI in Pregnancy
Antidepressant use in reproductive-aged women has increased over the last decades,1 but there is little guidance on the management of treatment for women who become pregnant.2 Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the most commonly used classes of antidepressants in pregnant women,3 and it is consistently reported that approximately half of women discontinue use before or during pregnancy.4,5 While most pregnant women use SSRIs or SNRIs for depression or anxiety, such medications are also used in women being treated for other psychiatric conditions (eg, insomnia, obsessive-compulsive disorder, eating disorders, and bipolar or psychotic disorders),3 which are known to carry a higher risk for adverse postpartum psychiatric outcomes.6
- Open Access
- 21 March 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (4) , e5780
Consistency between the National Patient Register and the Swedish Cancer Register
Purpose: The Swedish National Patient Register (NPR) is widely used as a data source in epidemiological studies, but the consistency of all cancer diagnoses compared to the Swedish Cancer Register (SCR) remains unclear. Using NPR supplementary for detecting safety signals is beneficial due to shorter data extraction delays compared to using SCR alone. This study aims to evaluate the consistency of NPR for cancer diagnoses compared to SCR and its potential use in pharmacoepidemiology.Methods: Patients with a cancer diagnosis recorded in SCR during 2018–2020 were included. To measure the consistency of NPR diagnoses with SCR as the gold standard, positive predictive value (PPV), and sensitivity were calculated. As an empirical example showing differences in identification of cancer diagnoses in NPR and SCR, two nested case–control studies for the association between antidiabetic medications and pancreatic cancer were repeated using the two registers. Conditional logistic regression was performed and the 95% confidence intervals (CIs) for the odds ratios (ORs) were checked for overlaps.Results: For breast, male genital organs, and oral cancers consistency was high (PPV: 87.5%–97.4%, sensitivity: 82.2%–91.0%), while for female genital organs, thyroid, and ill‐defined, secondary, and unspecified sites cancers it was low (PPV: 8.8%–90.0%, sensitivity: 19.9%–32.3%). All the CIs for the ORs from the nested case–control studies overlapped when pancreatic cancer was identified in NPR or SCR.Conclusion: Consistency of cancer diagnoses in NPR when compared to SCR depends on cancer type with higher consistency for some cancers and lower for others. Differences in diagnostic processes for different cancer types and coding of cancer in the two registers may explain part of the inconsistent results.
- 21 March 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (4) , e5780
Open AccessConsistency between the National Patient Register and the Swedish Cancer Register
Purpose: The Swedish National Patient Register (NPR) is widely used as a data source in epidemiological studies, but the consistency of all cancer diagnoses compared to the Swedish Cancer Register (SCR) remains unclear. Using NPR supplementary for detecting safety signals is beneficial due to shorter data extraction delays compared to using SCR alone. This study aims to evaluate the consistency of NPR for cancer diagnoses compared to SCR and its potential use in pharmacoepidemiology.Methods: Patients with a cancer diagnosis recorded in SCR during 2018–2020 were included. To measure the consistency of NPR diagnoses with SCR as the gold standard, positive predictive value (PPV), and sensitivity were calculated. As an empirical example showing differences in identification of cancer diagnoses in NPR and SCR, two nested case–control studies for the association between antidiabetic medications and pancreatic cancer were repeated using the two registers. Conditional logistic regression was performed and the 95% confidence intervals (CIs) for the odds ratios (ORs) were checked for overlaps.Results: For breast, male genital organs, and oral cancers consistency was high (PPV: 87.5%–97.4%, sensitivity: 82.2%–91.0%), while for female genital organs, thyroid, and ill‐defined, secondary, and unspecified sites cancers it was low (PPV: 8.8%–90.0%, sensitivity: 19.9%–32.3%). All the CIs for the ORs from the nested case–control studies overlapped when pancreatic cancer was identified in NPR or SCR.Conclusion: Consistency of cancer diagnoses in NPR when compared to SCR depends on cancer type with higher consistency for some cancers and lower for others. Differences in diagnostic processes for different cancer types and coding of cancer in the two registers may explain part of the inconsistent results.
- Open Access
- 7 November 2023
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 42 (1) , 1-15
A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes
Background: Antidiabetic medication adherence is a key aspect for successful control of type 2 diabetes mellitus (T2DM). This systematic review aims to provide an overview of the associations between socioeconomic factors and antidiabetic medication adherence in individuals with T2DM.Methods: A study protocol was established using the PRISMA checklist. A primary literature search was conducted during March 2022, searching PubMed, Embase, Web of Science, as well as WorldCat and the Bielefeld Academic Search Engine. Studies were included if published between 1990 and 2022 and included individuals with T2DM. During primary screening, one reviewer screened titles and abstracts for eligibility, while in the secondary screening, two reviewers worked independently to extract the relevant data from the full-text articles.Results: A total of 15,128 studies were found in the primary search, and 102 were finally included in the review. Most studies found were cross-sectional (72) and many investigated multiple socioeconomic factors. Four subcategories of socioeconomic factors were identified: economic (70), social (74), ethnical/racial (19) and geographical (18). The majority of studies found an association with antidiabetic medication adherence for two specific factors, namely individuals’ insurance status (10) and ethnicity or race (18). Other important factors were income and education.Conclusions: A large heterogeneity between studies was observed, with many studies relying on subjective data from interviewed individuals with a potential for recall bias. Several socioeconomic groups influencing medication adherence were identified, suggesting potential areas of intervention for the improvement of diabetes treatment adherence and individuals’ long-term well-being.
- 7 November 2023
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 42 (1) , 1-15
Open AccessA global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes
Background: Antidiabetic medication adherence is a key aspect for successful control of type 2 diabetes mellitus (T2DM). This systematic review aims to provide an overview of the associations between socioeconomic factors and antidiabetic medication adherence in individuals with T2DM.Methods: A study protocol was established using the PRISMA checklist. A primary literature search was conducted during March 2022, searching PubMed, Embase, Web of Science, as well as WorldCat and the Bielefeld Academic Search Engine. Studies were included if published between 1990 and 2022 and included individuals with T2DM. During primary screening, one reviewer screened titles and abstracts for eligibility, while in the secondary screening, two reviewers worked independently to extract the relevant data from the full-text articles.Results: A total of 15,128 studies were found in the primary search, and 102 were finally included in the review. Most studies found were cross-sectional (72) and many investigated multiple socioeconomic factors. Four subcategories of socioeconomic factors were identified: economic (70), social (74), ethnical/racial (19) and geographical (18). The majority of studies found an association with antidiabetic medication adherence for two specific factors, namely individuals’ insurance status (10) and ethnicity or race (18). Other important factors were income and education.Conclusions: A large heterogeneity between studies was observed, with many studies relying on subjective data from interviewed individuals with a potential for recall bias. Several socioeconomic groups influencing medication adherence were identified, suggesting potential areas of intervention for the improvement of diabetes treatment adherence and individuals’ long-term well-being.